U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,472.87
    +689.04 (+2.90%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The White House unveiled the first phase of its national monkeypox vaccine strategy, with plans to send doses to areas with confirmed outbreaks.

  • The U.S. Department of Health and Human Services plans to distribute 296,000 doses of the Bavarian Nordic A/S's (OTC: BVNRYJynneos vaccine, an already-developed monkeypox vaccine.

  • The U.S. is releasing 56,000 doses of the Jynneos vaccine from the strategic national stockpile, and 240,000 doses will follow in the coming weeks.

  • Related: EU, Bavarian Nordic Ink Supply Pact For 110,000 Monkeypox Vaccines.

  • HHS expects more than 750,000 doses to be made available over the summer. An additional 500,000 doses will undergo completion, inspection, and release throughout the fall, totaling 1.6 million doses available this year.

  • As per the White House statement, State and local health departments can also order supplies of Emergent BioSolutions Inc's (NYSE: EBSACAM2000 smallpox vaccine.

  • ACAM2000 carries a greater risk of certain serious side effects than Jynneos and cannot be provided to individuals who are immunocompromised or have heart disease.

  • Price Action: EBS shares closed at $31.25 on Tuesday.

  • Photo by Gerd Altmann from Pixabay

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.